TY - JOUR
T1 - Defeating antibiotic-resistant bacteria
T2 - Exploring alternative therapies for a post-antibiotic era
AU - Wang, Chih Hung
AU - Hsieh, Yi Hsien
AU - Powers, Zachary M.
AU - Kao, Cheng Yen
N1 - Publisher Copyright:
© 2020 by the authors. Licensee MDPI, Basel, Switzerland.
PY - 2020/2/1
Y1 - 2020/2/1
N2 - Antibiotics are one of the greatest medical advances of the 20th century, however, they are quickly becoming useless due to antibiotic resistance that has been augmented by poor antibiotic stewardship and a void in novel antibiotic discovery. Few novel classes of antibiotics have been discovered since 1960, and the pipeline of antibiotics under development is limited. We therefore are heading for a post-antibiotic era in which common infections become untreatable and once again deadly. There is thus an emergent need for both novel classes of antibiotics and novel approaches to treatment, including the repurposing of existing drugs or preclinical compounds and expanded implementation of combination therapies. In this review, we highlight to utilize alternative drug targets/therapies such as combinational therapy, anti-regulator, anti-signal transduction, anti-virulence, anti-toxin, engineered bacteriophages, and microbiome, to defeat antibiotic-resistant bacteria.
AB - Antibiotics are one of the greatest medical advances of the 20th century, however, they are quickly becoming useless due to antibiotic resistance that has been augmented by poor antibiotic stewardship and a void in novel antibiotic discovery. Few novel classes of antibiotics have been discovered since 1960, and the pipeline of antibiotics under development is limited. We therefore are heading for a post-antibiotic era in which common infections become untreatable and once again deadly. There is thus an emergent need for both novel classes of antibiotics and novel approaches to treatment, including the repurposing of existing drugs or preclinical compounds and expanded implementation of combination therapies. In this review, we highlight to utilize alternative drug targets/therapies such as combinational therapy, anti-regulator, anti-signal transduction, anti-virulence, anti-toxin, engineered bacteriophages, and microbiome, to defeat antibiotic-resistant bacteria.
KW - Alternative therapies
KW - Antibiotic resistance
KW - Regulator
KW - Signal transduction
KW - Virulence factors
UR - http://www.scopus.com/inward/record.url?scp=85079082029&partnerID=8YFLogxK
U2 - 10.3390/ijms21031061
DO - 10.3390/ijms21031061
M3 - Review article
C2 - 32033477
AN - SCOPUS:85079082029
SN - 1661-6596
VL - 21
JO - International Journal Of Molecular Sciences
JF - International Journal Of Molecular Sciences
IS - 3
M1 - 1061
ER -